clinical trial · NCT05806814
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
University of Oklahoma·phase1·recruiting·n = 13
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Sipuleucel-T
brief summary
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
started
Nov 12, 2023
primary completion
Jun 1, 2026
completion
Dec 1, 2026
last updated
Mar 5, 2026
detailed description
This open-label, pilot trial aims to evaluate the feasibility of Sipuleucel-T given in three doses at weeks 0, 2, and 12-14; and to investigate the changes in immune response in mCRPC patients who are getting an extended course of Sipuleucel-T treatment.
official title
Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol